Collaboration Medical Valuation 
Sun Acquisitions
FEBRUARY 26, 2024
Business photo created by rawpixel.com – www.freepik.com CHICAGO, IL – February 23, 2024 – A distinguished specialty plastics provider for medical devices out of Northern California, has initiated a sell-side engagement represented by Sun Acquisitions.
Devensoft
AUGUST 22, 2023
Navigating M&A valuations with precision is paramount for informed decision-making. Our guide equips you with step-by-step instructions on employing the Enterprise Value Calculator effectively, complete with insights into optimal practices for precision valuations. Let’s dive into the intricacies of this invaluable resource.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sun Acquisitions
FEBRUARY 6, 2023
continues their goal of acquiring and integrating leading medical aesthetics clinics, enabling medical professionals in their subsidiaries to achieve personal and professional goals while creating world-class customer experiences by networking support, collaboration, and community. About MedSpa Partners Inc.
Software Equity Group
MARCH 26, 2024
Main Capital has made 215 total investments since its founding, with current assets under management (AUM) of $2.37B and an active portfolio of 47 firms, with a median valuation of $10.25M. Thoma Bravo maintains an active portfolio of 76 firms, with $134B in AUM and a $435M median valuation. The firm currently employs 31 professionals.
Tyton Partners
FEBRUARY 3, 2025
This stability will also enhance valuation certainty, encouraging sellers who had been hesitant due to market volatility to re-enter the market. We wish you a prosperous New Year and look forward to the opportunity to collaborate with you in the near future.
Cooley M&A
JANUARY 25, 2023
Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.
Cooley M&A
JANUARY 23, 2024
Valuation disconnects persist In the post-COVID era, the life sciences market has experienced an increased polarization of successful and distressed companies, with sharp contrasts in liquidity and investment interest as buyers focus on de-risked assets. Collaborate or buy?’
Expert insights. Personalized for you.
52 
Let's personalize your content